E
Elisa de Stanchina
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 268
Citations - 26387
Elisa de Stanchina is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 65, co-authored 201 publications receiving 21076 citations. Previous affiliations of Elisa de Stanchina include Kettering University & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Catherine B. Meador,Hailing Jin,Elisa de Stanchina,Caroline A. Nebhan,Valentina Pirazzoli,Lu Wang,Pengcheng Lu,Huy Vuong,Katherine E. Hutchinson,Peilin Jia,Xi Chen,Rosana Eisenberg,Marc Ladanyi,Katerina Politi,Zhongming Zhao,Christine M. Lovly,Darren Cross,William Pao +17 more
TL;DR: It is found that AZD9291 was more potent than A+C at inhibiting cell growth and EGFR signaling in this setting, and provides a framework for future clinical trials testing different treatment sequences.
Journal ArticleDOI
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing.
Sara Parsa,Ana Ortega-Molina,Hsia-Yuan Ying,Man Jiang,Matt Teater,Jiahui Wang,Chunying Zhao,Ed Reznik,Joyce P. Pasion,David Kuo,Prathibha Mohan,Shenqiu Wang,Jeannie M. Camarillo,Paul M. Thomas,Neeraj Jain,Javier Garcia-Bermudez,Byoung-Kyu Cho,Wayne Tam,Neil L. Kelleher,Nicholas D. Socci,Ahmet Dogan,Elisa de Stanchina,Giovanni Ciriello,Giovanni Ciriello,Michael R. Green,Sheng Li,Kıvanç Birsoy,Ari Melnick,Hans-Guido Wendel +28 more
TL;DR: Findings reveal that amplification of SHMT2 in cooperation with BCL2 is sufficient in the initiation of lymphomagenesis through epigenetic tumor suppressor silencing.
Journal ArticleDOI
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor
Benedikt Bosbach,Shayu Deshpande,Ferdinand Rossi,Jae-Hung Shieh,Gunhild Sommer,Elisa de Stanchina,Darren R. Veach,Joseph M. Scandura,Katia Manova-Todorova,Malcolm A.S. Moore,Cristina R. Antonescu,Peter Besmer +11 more
TL;DR: This mouse model should be useful for preclinical studies of drug candidates designed to overcome imatinib resistance in GIST and to investigate the consequences of oncogenic KIT signaling in hematopoietic as well as other cell lineages.
Journal ArticleDOI
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Jonathan Cooper,Jonathan Cooper,Qingwen Xu,Lu Zhou,Milica Pavlovic,Milica Pavlovic,Virginia Ojeda,Kamalika Moulick,Elisa de Stanchina,John T. Poirier,Marjorie G. Zauderer,Marjorie G. Zauderer,Charles M. Rudin,Matthias A. Karajannis,C. Oliver Hanemann,Filippo G. Giancotti +15 more
TL;DR: It is shown that MLN4924, a NEDD8-activating enzyme (NAE) inhibitor, suppresses CRL4DCAF1 and attenuates activation of YAP in NF2-mutant tumor cells, and provides preclinical rationale for the use of NAE inhibitors in combination with mTOR/PI3K inhibitors in NF 2-mutants tumors.
Journal ArticleDOI
Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles.
Feng Chen,Brian Madajewski,Kai Ma,Daniella Karassawa Zanoni,Hilda Stambuk,Melik Z. Turker,Sebastien Monette,Li Zhang,Barney Yoo,Peiming Chen,Richard J. C. Meester,Sander de Jonge,Pablo H. Montero,Evan H. Phillips,Thomas P. Quinn,Mithat Gonen,Sonia Sequeira,Elisa de Stanchina,Pat Zanzonico,Ulrich Wiesner,Snehal G. Patel,Michelle S. Bradbury +21 more
TL;DR: B batches of spectrally distinct 6-nm near-infrared fluorescent core-shell silica nanoparticles are developed, each batch surface-functionalized with different melanoma targeting ligands and accurately detected and molecularly phenotyped cancerous nodes in a spontaneous melanoma miniswine model using image-guided multiplexing tools.